Production (Stage)
LENZ Therapeutics, Inc.
LENZ
$31.96
$1.665.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.74M | -49.77M | -60.81M | -69.47M | -73.95M |
| Total Depreciation and Amortization | 89.00K | 58.00K | 37.00K | 31.00K | 17.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.20M | 3.41M | 2.93M | 2.17M | 1.72M |
| Change in Net Operating Assets | -7.05M | -13.09M | -13.44M | -6.52M | 686.00K |
| Cash from Operations | -51.50M | -59.39M | -71.28M | -73.79M | -71.52M |
| Capital Expenditure | -578.00K | -468.00K | -319.00K | -133.00K | -24.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -153.01M | -154.01M | -127.12M | -83.00M | -11.59M |
| Cash from Investing | -153.59M | -154.48M | -127.44M | -83.13M | -11.62M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 29.93M | 83.70M | 83.65M | 53.82M | 53.82M |
| Repurchase of Common Stock | -150.00K | -150.00K | -150.00K | -150.00K | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.00M | 115.45M | 113.54M | 112.99M | 114.97M |
| Cash from Financing | 27.78M | 199.00M | 197.04M | 166.65M | 168.79M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.32M | -14.87M | -1.69M | 9.73M | 85.66M |